 Johny Nguyen
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graves Ophthalmopathy | 6 | 2023 | 14 | 1.340 |
Why?
| | Eyelid Diseases | 4 | 2017 | 21 | 1.070 |
Why?
| | Orbit | 7 | 2021 | 59 | 1.010 |
Why?
| | Surgery, Plastic | 1 | 2023 | 25 | 0.880 |
Why?
| | Ophthalmology | 2 | 2023 | 77 | 0.840 |
Why?
| | Oculomotor Muscles | 2 | 2017 | 40 | 0.670 |
Why?
| | Eyelids | 2 | 2023 | 29 | 0.620 |
Why?
| | Ectropion | 1 | 2018 | 2 | 0.620 |
Why?
| | Eye Movements | 2 | 2023 | 53 | 0.610 |
Why?
| | Ichthyosis, Lamellar | 1 | 2018 | 10 | 0.610 |
Why?
| | Thalidomide | 1 | 2018 | 28 | 0.600 |
Why?
| | Eye Infections, Bacterial | 2 | 2013 | 26 | 0.500 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 299 | 0.500 |
Why?
| | Hemangioma | 3 | 2010 | 41 | 0.490 |
Why?
| | Exophthalmos | 3 | 2023 | 19 | 0.470 |
Why?
| | Debridement | 1 | 2014 | 73 | 0.450 |
Why?
| | Decompression, Surgical | 1 | 2014 | 93 | 0.440 |
Why?
| | Orbital Myositis | 1 | 2012 | 2 | 0.420 |
Why?
| | Surgical Wound Infection | 2 | 2013 | 248 | 0.420 |
Why?
| | Eye Enucleation | 2 | 2013 | 12 | 0.410 |
Why?
| | Orbital Implants | 2 | 2012 | 2 | 0.410 |
Why?
| | Eikenella corrodens | 1 | 2012 | 1 | 0.400 |
Why?
| | Orbital Fractures | 1 | 2012 | 9 | 0.400 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2012 | 37 | 0.390 |
Why?
| | Orbital Diseases | 1 | 2012 | 25 | 0.390 |
Why?
| | Abscess | 1 | 2012 | 72 | 0.380 |
Why?
| | Colitis, Ulcerative | 1 | 2012 | 105 | 0.370 |
Why?
| | Tomography, X-Ray Computed | 7 | 2017 | 2279 | 0.330 |
Why?
| | Facial Neoplasms | 1 | 2009 | 17 | 0.320 |
Why?
| | Lacrimal Apparatus | 3 | 2014 | 10 | 0.320 |
Why?
| | Eye, Artificial | 1 | 2008 | 1 | 0.310 |
Why?
| | Conjunctival Neoplasms | 1 | 2008 | 7 | 0.300 |
Why?
| | Lacrimal Apparatus Diseases | 3 | 2014 | 4 | 0.290 |
Why?
| | Nasolacrimal Duct | 2 | 2021 | 7 | 0.280 |
Why?
| | Calcinosis | 1 | 2008 | 242 | 0.260 |
Why?
| | Pamphlets | 1 | 2023 | 24 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2008 | 577 | 0.210 |
Why?
| | Comprehension | 1 | 2023 | 155 | 0.200 |
Why?
| | Vision Screening | 1 | 2021 | 9 | 0.190 |
Why?
| | Papilloma, Inverted | 1 | 2021 | 1 | 0.190 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2021 | 17 | 0.190 |
Why?
| | Humans | 27 | 2023 | 114623 | 0.180 |
Why?
| | Eyelid Neoplasms | 1 | 2020 | 8 | 0.180 |
Why?
| | Orbital Neoplasms | 2 | 2010 | 21 | 0.180 |
Why?
| | Vision Disorders | 1 | 2021 | 130 | 0.170 |
Why?
| | Eye Neoplasms | 2 | 2010 | 16 | 0.170 |
Why?
| | Propranolol | 2 | 2010 | 49 | 0.170 |
Why?
| | Middle Aged | 11 | 2021 | 26719 | 0.170 |
Why?
| | Carcinoma, Basal Cell | 1 | 2020 | 68 | 0.160 |
Why?
| | Patient Education as Topic | 1 | 2023 | 680 | 0.160 |
Why?
| | Male | 16 | 2021 | 55554 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 858 | 0.150 |
Why?
| | Cicatrix | 1 | 2018 | 50 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2010 | 287 | 0.140 |
Why?
| | Metabolome | 1 | 2020 | 282 | 0.140 |
Why?
| | Visual Acuity | 2 | 2021 | 274 | 0.140 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 36 | 0.130 |
Why?
| | Metabolomics | 1 | 2020 | 521 | 0.130 |
Why?
| | Eye | 1 | 2016 | 98 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 4411 | 0.120 |
Why?
| | Nerve Compression Syndromes | 1 | 2014 | 25 | 0.120 |
Why?
| | Biomarkers, Tumor | 4 | 2020 | 1040 | 0.120 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2014 | 25 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 12542 | 0.110 |
Why?
| | Wounds and Injuries | 1 | 2021 | 745 | 0.110 |
Why?
| | Eye Evisceration | 1 | 2013 | 1 | 0.110 |
Why?
| | Anti-Bacterial Agents | 2 | 2013 | 1477 | 0.110 |
Why?
| | Female | 14 | 2021 | 59466 | 0.110 |
Why?
| | Piezosurgery | 1 | 2013 | 1 | 0.110 |
Why?
| | Therapeutic Irrigation | 1 | 2013 | 67 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 382 | 0.100 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 96 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1262 | 0.100 |
Why?
| | Maxillary Fractures | 1 | 2012 | 2 | 0.100 |
Why?
| | Zygomatic Fractures | 1 | 2012 | 3 | 0.100 |
Why?
| | Methylprednisolone | 1 | 2012 | 81 | 0.100 |
Why?
| | Eye Diseases | 1 | 2013 | 76 | 0.100 |
Why?
| | Infliximab | 1 | 2012 | 94 | 0.100 |
Why?
| | Adult | 10 | 2022 | 30528 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2023 | 9084 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2012 | 1121 | 0.100 |
Why?
| | Osteotomy | 1 | 2013 | 146 | 0.100 |
Why?
| | Aged | 8 | 2021 | 19061 | 0.100 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2009 | 57 | 0.100 |
Why?
| | Intubation | 1 | 2011 | 4 | 0.090 |
Why?
| | Drainage | 1 | 2012 | 151 | 0.090 |
Why?
| | Dacryocystorhinostomy | 1 | 2011 | 10 | 0.090 |
Why?
| | Lipoma | 1 | 2010 | 15 | 0.090 |
Why?
| | Scleral Diseases | 1 | 2010 | 2 | 0.090 |
Why?
| | Nevus, Blue | 1 | 2010 | 2 | 0.090 |
Why?
| | Conjunctiva | 1 | 2011 | 51 | 0.090 |
Why?
| | Liposarcoma | 1 | 2010 | 26 | 0.090 |
Why?
| | Corneal Diseases | 1 | 2010 | 33 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 56 | 0.090 |
Why?
| | Recurrence | 1 | 2012 | 935 | 0.080 |
Why?
| | Aminoquinolines | 1 | 2009 | 20 | 0.080 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2009 | 17 | 0.080 |
Why?
| | Choristoma | 1 | 2009 | 23 | 0.080 |
Why?
| | Vincristine | 1 | 2009 | 98 | 0.080 |
Why?
| | Tooth | 1 | 2009 | 41 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2009 | 217 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2012 | 532 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2023 | 5043 | 0.080 |
Why?
| | Eye Injuries, Penetrating | 1 | 2008 | 17 | 0.070 |
Why?
| | Epidermis | 1 | 2008 | 149 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2009 | 186 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2009 | 220 | 0.070 |
Why?
| | Adolescent | 5 | 2017 | 17831 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2009 | 497 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6344 | 0.060 |
Why?
| | Young Adult | 3 | 2014 | 10455 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1342 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 3 | 2010 | 3039 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2010 | 756 | 0.050 |
Why?
| | Quality of Life | 2 | 2023 | 2353 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2009 | 2186 | 0.050 |
Why?
| | West Virginia | 1 | 2021 | 8 | 0.050 |
Why?
| | Trauma Severity Indices | 1 | 2021 | 114 | 0.050 |
Why?
| | Biomechanical Phenomena | 1 | 2023 | 668 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2023 | 770 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 537 | 0.040 |
Why?
| | Infant | 2 | 2010 | 7959 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1660 | 0.040 |
Why?
| | Administration, Oral | 2 | 2013 | 728 | 0.040 |
Why?
| | Societies, Medical | 2 | 2016 | 663 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1879 | 0.040 |
Why?
| | Prospective Studies | 2 | 2021 | 6217 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 663 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 1430 | 0.040 |
Why?
| | Pregnancy | 1 | 2009 | 5517 | 0.040 |
Why?
| | Pilot Projects | 1 | 2021 | 1372 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1840 | 0.030 |
Why?
| | International Agencies | 1 | 2016 | 30 | 0.030 |
Why?
| | Child | 3 | 2010 | 18404 | 0.030 |
Why?
| | Photography | 1 | 2016 | 88 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 222 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2477 | 0.030 |
Why?
| | Postoperative Complications | 2 | 2013 | 2128 | 0.030 |
Why?
| | Organ Size | 1 | 2013 | 434 | 0.020 |
Why?
| | Intraoperative Complications | 1 | 2013 | 122 | 0.020 |
Why?
| | Postoperative Care | 1 | 2013 | 222 | 0.020 |
Why?
| | Reference Values | 1 | 2013 | 742 | 0.020 |
Why?
| | Factor XIII | 1 | 2010 | 7 | 0.020 |
Why?
| | Sclerostomy | 1 | 2010 | 4 | 0.020 |
Why?
| | S100 Proteins | 1 | 2010 | 38 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2010 | 89 | 0.020 |
Why?
| | Cryotherapy | 1 | 2010 | 16 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2014 | 510 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 103 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 213 | 0.020 |
Why?
| | Actins | 1 | 2010 | 381 | 0.020 |
Why?
| | Radiotherapy | 1 | 2009 | 176 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 442 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1167 | 0.020 |
Why?
| | Survival Rate | 1 | 2009 | 1644 | 0.020 |
Why?
| | Biomarkers | 1 | 2009 | 3408 | 0.010 |
Why?
| | United States | 1 | 2009 | 12176 | 0.010 |
Why?
|
|
Nguyen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|